- Tablets, oral 15 mg
Potentiates action of GABA, an inhibitory neurotransmitter, resulting in increased neuronal inhibition and CNS depression, especially in limbic system and reticular formation.
Well absorbed from GI tract. C max is approximately 20 ng/mL; T max is approximately 2 h.
Protein binding is 95%. Quazepam is present in breast milk (less than 0.1% of dose).
It is extensively metabolized in the liver to 2 active metabolites, 2-oxoquazepam and N-desalkyl-2-oxoquazepam.
Eliminated in the urine (31%) and feces (23%); only trace amounts of the unchanged drug are present in the urine. The half-life for the parent and 2-oxoquazepam is 39 h; the half-life for N-desalkyl-2-oxoquazepam is 73 h.
Special PopulationsRenal Function Impairment
The potential for excessive sedation or impaired coordination exists.Hepatic Function Impairment
The potential for excessive sedation or impaired coordination exists.Elderly
Elimination half-life of N-desalkyl-2-oxoquazepam is increased 2-fold compared with younger adults.Alcoholism
The potential for excessive sedation or impaired coordination exists.
Indications and Usage
Treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.
Hypersensitivity to any component of this product or to benzodiazepines; pregnancy; sleep apnea.
Dosage and AdministrationAdults
PO 15 mg at bedtime initially; may reduce to 7.5 mg once individual response is determined.Elderly patients
PO 7.5 mg at bedtime initially; if this is not effective, may increase to 15 mg after 1 to 2 nights. Attempt to reduce the nightly dosage after 1 to 2 nights.Debilitated patients
Attempt dosage reduction after 1 to 2 nights.
- Use the smallest possible effective dose.
Store between 68° and 77°F.
Drug InteractionsAlcohol, CNS depressants, psychotropic drugs
May cause additive CNS depressant effects. The incidence of complex behaviors (eg, sleep driving) may be increased. Use with caution. If complex behaviors occur, consider discontinuation of hypnotic-sedatives. Avoid concurrent use of alcohol.Clozapine
Coadministration may result in delirium, sedation, sialorrhea, and ataxia. Severe orthostatic hypotension and respiratory depression may occur when clozapine is added to or started with quazepam. Do not start clozapine with quazepam simultaneously. The addition of quazepam to an established clozapine regimen may carry less risk than adding clozapine to quazepam. Close clinical monitoring is warranted, especially during the first 48 h of coadministration.CYP2B6 substrates (eg, bupropion, efavirenz)
Plasma concentrations of these drugs may be elevated, increasing the risk of adverse events. Closely monitor patients for adverse reactions. If adverse events occur, consider discontinuing quazepam and giving an alternative anxiolytic agent.Digoxin
May increase serum digoxin concentrations and the risk of toxicity. Monitor digoxin concentrations and adjust the dose as needed.Disulfiram, nefazodone
Pharmacologic effects (eg, CNS depressant effects) of quazepam may be increased. If increased CNS depressant effects occur, the quazepam dose may need to be reduced.Hydantoins (eg, phenytoin)
Elevated hydantoin plasma concentrations with toxicity (eg, nystagmus, ataxia and other cerebellar signs) may occur, while the pharmacologic effects of quazepam may be decreased. Close clinical and serum concentration monitoring is warranted.Methadone
Severe potentiation of respiratory depressant effects (including death) may occur. Coadminister with caution and closely monitor the clinical response.Omeprazole
Quazepam concentrations and half-life may be increased, increasing the pharmacologic effects and risk of adverse reactions (eg, CNS depressant effects). Quazepam dosage reduction or increased dosing interval may be needed.Protease inhibitors (eg, ritonavir)
Quazepam concentrations may be elevated. Severe sedation and respiratory depression may occur. If coadministration cannot be avoided, close clinical monitoring is warranted.Rifamycins (eg, rifampin)
Quazepam concentrations and pharmacologic effects may be decreased. Monitor the clinical response to quazepam when a rifamycin is started or stopped. Adjust the quazepam dose as needed.Sodium oxybate
The pharmacologic effects of sodium oxybate and quazepam may be additive, resulting in an increase in sleep duration and CNS depression. Coadministration is contraindicated.
Daytime drowsiness (12%); headache (5%); dizziness, fatigue (2%); agitation, dysarthria, dystonia, hallucinations, irritability, sleep disturbances, stimulation.
Dry mouth (2%); dyspepsia (1%).
Changes in libido, incontinence, menstrual irregularities, urinary retention.
Increased eosinophils (2%); decreased hemoglobin, decreased lymphocytes, increased AST, increased monocytes (1%).
Increased muscle spasticity.
Monitor patients for worsening of insomnia and the emergence of new thinking or behavior abnormalities. Addiction-prone individuals should be under careful surveillance because of the predisposition of such patients to habituation and dependence. Monitor elderly patients, debilitated patients, and patients with impaired renal or hepatic function for excessive sedation or impaired coordination.
Category X . May cause fetal harm. Contraindicated in pregnancy.
Excreted in breast milk. Use in breast-feeding women is not recommended.
Safety and efficacy have not been established.
Use with caution and at reduced doses.
Use with caution.
Use with caution.
Special Risk Patients
Use drug with caution in patients with depression or suicidal tendencies, drug abuse and dependence, or chronic pulmonary insufficiency.
Prolonged use can lead to psychologic or physical dependence. Withdrawal syndrome may occur; dose must be tapered gradually.
Rare cases of angioedema involving the tongue, glottis, or larynx have been reported. Some patients have had additional symptoms (eg, dyspnea, throat closing, nausea and vomiting).
Sleep driving and other complex behaviors (eg, preparing and eating food, making phone calls, having sex) in patients who are not fully awake have been reported.
Signs and symptoms of depression may be intensified when depressed patients take benzodiazepines.
Caution patients about engaging in hazardous occupations requiring complete mental alertness, such as operating machinery or driving, after ingesting benzodiazepines. Potential impairment of the performance of such activities may occur the day following ingestion.
Unrecognized psychiatric or physical disorder
Worsening of insomnia or the emergence of new thinking or behavior abnormalities may be the consequence of an unrecognized psychiatric or physical disorder; such findings have emerged during treatment with sedative-hypnotics. Failure of insomnia to remit after 7 to 10 days of treatment may indicate presence of a disorder that should be evaluated.
Coma, confusion, somnolence.
- Instruct patient to read the Medication Guide before starting therapy and with each refill.
- Advise patients to report any complex behaviors (eg, sleep driving) to their health care provider immediately.
- Advise patients to inform their health care provider about any alcohol consumption and medications that they are taking, including OTC drugs. Advise patients that alcohol should generally not be consumed during treatment with hypnotics.
- Caution patients about the possible combined effects of alcohol and other CNS depressants. Caution patients that an additive effect may occur if alcohol is consumed during the day following the use of quazepam for nighttime sedation. The potential for this interaction continues for several days following discontinuation of quazepam until serum levels of psychoactive metabolites have declined.
- Advise patients to inform their health care provider if planning to become pregnant, if they are pregnant, of if they become pregnant during therapy.
- Advise patients to inform their health care provider if they are breast-feeding.
- Advise patients not to drive a car or operate potentially dangerous machinery until they know how this medicine affects them.
- Inform patients that this medicine may cause daytime sedation, which may persist for several days following drug discontinuation.
- Advise patients not to increase the dose on their own and to inform their health care provider if they believe the drug does not work anymore.
- If benzodiazepines are taken on a prolonged and regular basis (even for periods as brief as 6 wk), advise patients not to stop taking them abruptly or to decrease the dose without consulting their health care provider because withdrawal symptoms may occur.
Copyright © 2009 Wolters Kluwer Health.
More about quazepam
- Other brands: Doral